Skip to content

Study · Randomized controlled trial · n = 132 · 2025

8 results

A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass.

Lofton HF, Maranga G, Hold R, Fielding G, Youn H, Gujral A, Heffron S, Fielding C

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery10 Sept 2024Cited by 16 (Europe PMC)

PMID39401933 (opens in a new tab)DOI10.1016/j.soard.2024.08.037 (opens in a new tab)PepBankPUB-39401933
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    After Roux-en-Y gastric bypass, 76% with liraglutide and 17% with placebo achieved at least 5% total body weight loss at 56 weeks.

    In plain wordsAfter gastric bypass, 76% taking liraglutide and 17% taking placebo lost at least 5% of body weight.

    Peptide
    Liraglutide
    Outcome
    IncreaseAt least 5% total body weight loss at 56 weeks
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/d · 56 weeksAs given in this study (human).

    Measurements

    At least5% total-body-weight-loss responders
    76%
    liraglutide; 56 weeks
    At least5% total-body-weight-loss responders
    17%
    placebo; 56 weeks

    Source sentences

    Summary
    76% and 17% of subjects achieved ≥5% TBWL at 56 weeks in the liraglutide and placebo groups, respectively; 51% and 26.0% of the liraglutide group achieved ≥10% and ≥15% TBWL, respectively.
    3 context sentences
    Summary · context
    A 56-week, double-blind, placebo-controlled study was conducted in 132 subjects, who achieved ≥25% total body weight loss (TBWL) status-post-RYGB and regained ≥10% TBWL after reaching nadir weight (NW).
    Summary · context
    Subjects 18-120 months post-RYGB were randomized to receive liraglutide 3.0 mg/d (n = 89) or placebo (n = 43) with lifestyle counseling regularly for 56 weeks.
    Summary · context
    The co-primary endpoints were the proportion of subjects losing at least 5%, 10%, and 15% TBWL and achieving weight lower than their NW.
  2. 02HumanRandomized controlled trialEfficacy outcome

    After Roux-en-Y gastric bypass, 51% of liraglutide participants achieved at least 10% total body weight loss at 56 weeks, whereas none of the placebo group did.

    In plain wordsAfter gastric bypass, 51% taking liraglutide lost at least 10% of body weight, while no placebo participants did.

    Peptide
    Liraglutide
    Outcome
    IncreaseAt least 10% total body weight loss at 56 weeks
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/d · 56 weeksAs given in this study (human).

    Measurements

    At least10% total-body-weight-loss responders
    51%
    liraglutide; 56 weeks; no placebo participants reached threshold

    Source sentences

    Summary
    76% and 17% of subjects achieved ≥5% TBWL at 56 weeks in the liraglutide and placebo groups, respectively; 51% and 26.0% of the liraglutide group achieved ≥10% and ≥15% TBWL, respectively. None of the placebo group lost ≥10% TBWL.
    3 context sentences
    Summary · context
    A 56-week, double-blind, placebo-controlled study was conducted in 132 subjects, who achieved ≥25% total body weight loss (TBWL) status-post-RYGB and regained ≥10% TBWL after reaching nadir weight (NW).
    Summary · context
    Subjects 18-120 months post-RYGB were randomized to receive liraglutide 3.0 mg/d (n = 89) or placebo (n = 43) with lifestyle counseling regularly for 56 weeks.
    Summary · context
    The co-primary endpoints were the proportion of subjects losing at least 5%, 10%, and 15% TBWL and achieving weight lower than their NW.
  3. 03HumanRandomized controlled trialEfficacy outcome

    After Roux-en-Y gastric bypass, 26.0% of liraglutide participants achieved at least 15% total body weight loss at 56 weeks.

    In plain wordsAfter gastric bypass, 26.0% of people taking liraglutide lost at least 15% of body weight.

    Peptide
    Liraglutide
    Outcome
    IncreaseAt least 15% total body weight loss at 56 weeks
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/d · 56 weeksAs given in this study (human).

    Measurements

    At least15% total-body-weight-loss responders
    26%
    liraglutide; 56 weeks

    Source sentences

    Summary
    76% and 17% of subjects achieved ≥5% TBWL at 56 weeks in the liraglutide and placebo groups, respectively; 51% and 26.0% of the liraglutide group achieved ≥10% and ≥15% TBWL, respectively.
    3 context sentences
    Summary · context
    A 56-week, double-blind, placebo-controlled study was conducted in 132 subjects, who achieved ≥25% total body weight loss (TBWL) status-post-RYGB and regained ≥10% TBWL after reaching nadir weight (NW).
    Summary · context
    Subjects 18-120 months post-RYGB were randomized to receive liraglutide 3.0 mg/d (n = 89) or placebo (n = 43) with lifestyle counseling regularly for 56 weeks.
    Summary · context
    The co-primary endpoints were the proportion of subjects losing at least 5%, 10%, and 15% TBWL and achieving weight lower than their NW.
  4. 04HumanRandomized controlled trialEfficacy outcome

    After Roux-en-Y gastric bypass, twenty-one percent of subjects receiving liraglutide surpassed postoperative nadir weight, while no placebo subjects met this goal.

    In plain wordsAfter gastric bypass, twenty-one percent taking liraglutide went below their previous lowest weight, while no placebo participants did.

    Peptide
    Liraglutide
    Outcome
    IncreaseWeight below postoperative nadir
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/d · 56 weeksAs given in this study (human).

    Source sentences

    Summary
    Twenty-one percent of subjects receiving liraglutide surpassed postoperative NW. No subjects on placebo met this goal.
    3 context sentences
    Summary · context
    A 56-week, double-blind, placebo-controlled study was conducted in 132 subjects, who achieved ≥25% total body weight loss (TBWL) status-post-RYGB and regained ≥10% TBWL after reaching nadir weight (NW).
    Summary · context
    Subjects 18-120 months post-RYGB were randomized to receive liraglutide 3.0 mg/d (n = 89) or placebo (n = 43) with lifestyle counseling regularly for 56 weeks.
    Summary · context
    The co-primary endpoints were the proportion of subjects losing at least 5%, 10%, and 15% TBWL and achieving weight lower than their NW.
  5. 05HumanRandomized controlled trialOther

    In people with weight recurrence after RYGB, 65% of liraglutide and 53.4% of placebo recipients completed the 56-week trial during the pandemic.

    In plain wordsAfter gastric bypass weight recurrence, 65% taking liraglutide and 53.4% taking placebo completed the trial.

    Peptide
    Liraglutide
    Outcome
    IncreaseTrial completion
    Study

    n = 132

    Comparator
    Placebo
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    3.0 mg/d · 56 weeksAs given in this study (human).

    Measurements

    Trial completion
    65%
    liraglutide
    Trial completion
    53.4%
    placebo

    Source sentences

    Summary
    53.4% of the placebo group and 65% of the liraglutide group completed the trial due to Severe acute respiratory syndrome coronavirus 2 pandemic.
    3 context sentences
    Summary · context
    A 56-week, double-blind, placebo-controlled study was conducted in 132 subjects, who achieved ≥25% total body weight loss (TBWL) status-post-RYGB and regained ≥10% TBWL after reaching nadir weight (NW).
    Summary · context
    Subjects 18-120 months post-RYGB were randomized to receive liraglutide 3.0 mg/d (n = 89) or placebo (n = 43) with lifestyle counseling regularly for 56 weeks.
    Summary · context
    The co-primary endpoints were the proportion of subjects losing at least 5%, 10%, and 15% TBWL and achieving weight lower than their NW.
  6. 06HumanRandomized controlled trialEfficacy outcome

    After Roux-en-Y gastric bypass, percentage total body weight change at 56 weeks was -8.8 (8.5, -29.2 to 9.7) with liraglutide and 1.1 (3.5, -7.9 to 5.99) with placebo.

    In plain wordsAfter gastric bypass weight recurrence, weight change at 56 weeks was -8.8% with liraglutide versus +1.1% with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreasePercentage total body weight loss change at 56 weeks
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/d · 56 weeksAs given in this study (human).

    Measurements

    Percentage body-weight change
    −8.8%
    liraglutide; source parentheses 8.5, -29.2 to 9.7; dispersion type unspecified
    Percentage body-weight change
    1.1%
    placebo; source parentheses 3.5, -7.9 to 5.99; dispersion type unspecified

    Source sentences

    Summary
    The change in %TBWL from baseline to 56-weeks was -8.8 (8.5, -29.2 to 9.7) and 1.1 (3.5, -7.9 to 5.99) in the liraglutide and placebo groups, respectively.
    3 context sentences
    Summary · context
    A 56-week, double-blind, placebo-controlled study was conducted in 132 subjects, who achieved ≥25% total body weight loss (TBWL) status-post-RYGB and regained ≥10% TBWL after reaching nadir weight (NW).
    Summary · context
    Subjects 18-120 months post-RYGB were randomized to receive liraglutide 3.0 mg/d (n = 89) or placebo (n = 43) with lifestyle counseling regularly for 56 weeks.
    Summary · context
    The co-primary endpoints were the proportion of subjects losing at least 5%, 10%, and 15% TBWL and achieving weight lower than their NW.
  7. 07HumanRandomized controlled trialSafety outcome

    After Roux-en-Y gastric bypass, nonserious adverse events occurred in 41.6% of subjects on liraglutide.

    In plain wordsAfter gastric bypass, 41.6% of people taking liraglutide had nonserious side effects.

    Peptide
    Liraglutide
    Outcome
    Not applicableNonserious adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    3.0 mg/d · 56 weeksAs given in this study (human).

    Measurements

    Nonserious adverse events
    41.6%
    liraglutide recipients; analysed denominator unspecified

    Source sentences

    Summary
    Nonserious adverse events occurred in 41.6% of subjects on liraglutide.
    3 context sentences
    Summary · context
    A 56-week, double-blind, placebo-controlled study was conducted in 132 subjects, who achieved ≥25% total body weight loss (TBWL) status-post-RYGB and regained ≥10% TBWL after reaching nadir weight (NW).
    Summary · context
    Subjects 18-120 months post-RYGB were randomized to receive liraglutide 3.0 mg/d (n = 89) or placebo (n = 43) with lifestyle counseling regularly for 56 weeks.
    Summary · context
    The co-primary endpoints were the proportion of subjects losing at least 5%, 10%, and 15% TBWL and achieving weight lower than their NW.
  8. 08HumanRandomized controlled trialSafety outcome

    After Roux-en-Y gastric bypass, serious adverse events occurred less often with liraglutide than placebo.

    In plain wordsAfter gastric bypass, serious side effects were less common with liraglutide than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseSerious adverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    3.0 mg/d · 56 weeksAs given in this study (human).

    Source sentences

    Summary
    Serious adverse events (SAE) occurred less often on liraglutide.
    3 context sentences
    Summary · context
    A 56-week, double-blind, placebo-controlled study was conducted in 132 subjects, who achieved ≥25% total body weight loss (TBWL) status-post-RYGB and regained ≥10% TBWL after reaching nadir weight (NW).
    Summary · context
    Subjects 18-120 months post-RYGB were randomized to receive liraglutide 3.0 mg/d (n = 89) or placebo (n = 43) with lifestyle counseling regularly for 56 weeks.
    Summary · context
    The co-primary endpoints were the proportion of subjects losing at least 5%, 10%, and 15% TBWL and achieving weight lower than their NW.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.